THE EXPANDER-2 TRIAL

Struggling with lower urinary tract symptoms related to benign prostatic hyperplasia (BPH)?


See if the Expander-2 Trial might be right for you.


Approximately, 60% of men over the age of 60 and up to 80% of men overall, will eventually develop BPH with LUTS, of which 30% will require treatment¹.

Normal Prostate

Enlarged Prostate

WHAT IS BENIGN PROSTATIC HYPERPLASIA

AND HOW DOES IT AFFECT YOUR LIFE?

Common LUTS related to BPH include:

• Poor or intermittent urine stream

• Difficulty to urinate

• Sudden urge to urinate

• Waking up frequently at night to urinate

• Having to urinate frequently

• Feeling of incomplete bladder emptying

Benign Prostatic Hyperplasia (BPH) is a condition where the prostatic tissue grows over time and obstructs the urethral lumen, leading to Lower Urinary Tract Symptoms (LUTS).

HOW DOES THE EXPANDER-2 TRIAL WORK?

Trial participants will be required to go off their BPH medications for the duration of the trial (under the supervision of a doctor).


The Expander-2 clinical trial objective is to evaluate the safety and efficacy of the Urocross™ System and the procedure to treat patients with symptomatic BPH. The Expander-2 Trial is a blinded study, meaning that participants will not be told whether they are receiving the investigational treatment or not. Participants who do not receive the investigational treatment will be eligible to cross over to the investigational treatment group after the unblinding (after 3 months).


Trial participants will be required to attend follow-up appointments to evaluate their progress at 1 week* and 2 weeks, at 1-, 3-, and 6- months, as well as 1-, 2-, and 3- years post-treatment.

*1-week follow-up will be by telephone for pain assessment.

Watch an animation of the procedure

FIND OUT IF YOU MIGHT BE A CANDIDATE

Find out now if you might qualify to join the Expander-2 Trial and receive an investigational drug-free treatment at no cost. If it appears you might be qualified to join the trial, a patient education specialist will reach out to provide more information and further qualify you for the study.

CAUTION: the Urocross™ Expander System is for Investigational Use Only and is not for sale in the U.S. or outside the U.S.

  1. Management of Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms: AUA Guideline 2021

© 2022 83Bar

Document # PM-1478 Ver. 2.0